BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
righst issue of units 2022 banner

BioStock: The five best life science stocks of the first half-year

PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
PHI-worldtour-1024x576

BioStock: PHI’s CEO reflects on global roadshow success

BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
Biostock-PHI-on-how-TO-3-proceeds-will-be-used

BioStock: PHI on how TO 3 proceeds will be used

BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.
1…45678…10

Latest News

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 December 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

The Board of Directors of Phase Holographic Imaging PHI AB has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024. The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company’s capital structure by repayment/off-setting of outstanding loans.

Adopting the final Annual Report

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
See All News